The Jewish people: Their ethnic history, genetic disorders and specific cancer susceptibility

Familial Cancer

Volumn 3, Issue 3-4, 2004, Pages 193-199

  Kedar Barnes, Inbal ^a   Paul, Rozen ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Ashkenazi; cancer susceptibility; ethnic; genetic diseases; Jews; Oriental; Sephardi

Indexed keywords

ARTICLE; BLOOM SYNDROME; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; ETHNOLOGY; FANCONI ANEMIA; GAUCHER DISEASE; GENE MUTATION; GENETIC DISORDER; GENETIC DRIFT; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GEOGRAPHY; HUMAN; LANGUAGE; LYSOSOME STORAGE DISEASE; MIGRATION; MISSENSE MUTATION; NIEMANN PICK DISEASE; PRIORITY JOURNAL; RELIGION; TAY SACHS DISEASE;

FEMALE; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; ISRAEL; JEWS; MALE; NEOPLASMS; PREVALENCE; RISK ASSESSMENT;

EID: 8544231423     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-004-9544-0     Document Type: Article

References (37)

1. Sachar AL. A history of the Jews, 5th edition. New York: A.A. Knof 1965.
2. Goodman RM. Genetic disorders among the Jewish People. Baltimore, Maryland: Johns Hopkins University Press 1979.
3. Statistic Abstracts of Israel, Central Bureau of Statistics, Jerusalem. Government Press 2000; 84-85.
4. Bonné-Tamir B, Ashbel S, Kennet R. Genetic markers: benign and normal traits of Ashkenazi Jews. In Goodman RM, Motulsky AG (eds): Genetic Diseases Among Ashkenazi Jews. New York: Raven Press 1979; 54-76.
5. Ritte U, Neufeld E, Broit M et al. The differences among Jewish communities-maternal and paternal contributions. J Mol Evol 1993; 37: 435-40.
6. Hammer MF, Redd AJ, Wood ET et al. Jewish and Middle Eastern non-Jewish populations share a common pool of Y-chromosome biallelic haplotypes. Proc Natl Acad Sci 2000; 97: 6769-74.
7. Nebel A, Filon D, Brinkmann B et al. The Y chromosome pool of Jews as part of the genetic landscape of the Middle East. Am J Hum Genet 2001; 69: 1095-112.
8. Thomas MG, Weale ME, Jones AL et al. Founding mothers of Jewish communities: geographically separated Jewish groups were independently founded by few female ancestors. Am J Hum Genet 2002; 70: 1411-20.
9. MIM Statistics (March 2003). Retrieved from http:// www.ncbi.nlm.nih.gov/ Omim/Stats/mimstars.html on 1 June 2004.
10. Goodman RM, Motulsky AG (eds): Genetic Diseases among Ashkenazi Jews. New York: Raven Press 1979.
11. Navon R, Proia RL. Tay Sachs Disease mutations among Moroccan Jews. In Bonné-Tamir B and Adam A (eds): Genetic Diversity Among Jews. New York: Oxford University Press 1992.
12. Peterson GM, Rotter JI, Cantor RM et al. The Tay-Sachs disease gene in North American Jewish populations: geographic variations and origin. Am J Hum Genet 1983; 35: 1258-69.
13. Risch N, Tang H, Katzenstein H, Ekstein J. Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am J Genet 2003; 72: 812-22.
14. Zlotogora J, Bach G. The possibility of a selection process in the Ashkenazi Jewish population. Am J Genet 2003; 73: 438-40.
15. Peleg L, Pesso R, Goldman B et al. Bloom syndrome and Fanconi's Anemia: rate and ethnic origin of mutation carriers in Israel. Isr Med Assoc J 2002; 4: 95-7.
16. Lowy A, Kordich JJ, Gismondi V et al. Numerous colonie adenomas in an individual with Bloom's syndrome. Gastroenterology 2001; 121: 435-9.
17. Auerbach AD. Fanconi Anemia and leukemia: tracking the genes. Leukemia 1992; 6 (Suppl 1): 1-4.
18. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822-6.
19. Tamary H, Bar-Yam R, Shalmon L et al. Fanconi anaemia group A (FANCA) mutations in Israeli non-Ashkenazi Jewish patients. Br J Haematol 2000; 111: 338-43.
20. Howlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi Anemia. Science 2002; 297: 606-9.
21. Offit K, Levran O, Mullaney B et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003; 95: 1548-51.
22. Fitzgerald MG, MacDonald DJ, Krainer M et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334: 143-9.
23. Bruchim Bar-Sade R, Theodor L, Gak E et al. Could the 185delAG BRCA1 mutation be an ancient Jewish mutation? Eur J Hum Gene 1997; 51: 413-16.
24. Bruchim Bar-Sade R, Kruglikova A, Modan B et al. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim. Hum Mol Genet 1998; 7: 801-5.
25. Shiri-Sverdlov R. Gershoni-Baruch R, Ichezkel-Hirsch G et al. The Tyr978X BRCA1 mutation in non-Ashkenazi Jews: occurrence in high-risk families, general population and unselected ovarian cancer patients. Community Genet 2001; 4: 50-5.
26. Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996; 14: 188-90.
27. Neuhausen S, Gilewski LN, Tran T et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13: 126-8.
28. Levy-Lahad E, Catane R, Eisenberg S et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60: 1059-67.
29. Lerer I, Wang T, Peretz T et al. The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 1998; 63: 272-4.
30. Abeliovich D, Kaduri L, Lerer I et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997; 60: 505-14.
31. Laken SJ, Petersen GM, Gruber SB et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997; 17: 79-83.
32. Rozen P, Naiman T, Strul H et al. Clinical and screening implications of the I1307K adenomatous polyposis coli gene variant in Israeli Ashkenazi Jews with familial colorectal neoplasia. Evidence for a founder effect. Cancer 2002; 94; 2561-8.
33. Chen-Shtoyerman R, Theodor L, Harmati E et al. Genetic analysis of familial colorectal cancer in Israeli Arabs. Hum Mut 2003; 21: 446-7.
34. Foulkes WD, Thiffault I, Gruber SB et al. The founder mutation MSH2*1906G>C is an important cause of hereditary non-polyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 2002; 71: 1395-412.
35. Guillem JG, Rapaport BS, Kirchhoff T et al. A636P is associated with early-onset colon cancer in Ashkenazi Jews. J Am Coll Surg 2003; 196: 222-5.
36. Rozen P, Samuel Z, Brazowski E. A prospective study of the clinical, genetic, screening and pathological features of a family with hereditary mixed polyposis syndrome. Am J Gastroenterol 2003; 98: 2317-20.
37. Jaeger EEM, Woodford-Richens KL, Lockett M et al. An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome. Am J Hum Genet 2003; 72: 1261-7.